



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **YAMADA, Yoshiji, et al.**

Group Art Unit: **3762**

Serial No.: **10/517,605**

Examiner: **Not Yet Assigned**

Filed: **December 21, 2004**

P.T.O. Confirmation No.: **1240**

For. **METHOD OF DIAGNOSING RISK OF MYOCARDIAL INFARCTION**

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

February 22, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed herewith is a copy of the Supplementary European Search Report along with copies of the references cited therein. The Supplementary European Search Report was cited during the prosecution of the corresponding European patent application No. 03712817.0 (PCT/JP0303477).

The undersigned hereby certifies

XX that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this statement.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

In the event that any fees are due in connection with this paper, please charge our Deposit Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,
HANSON & BROOKS, LLP


Daniel A. Geselowitz, Ph.D.
Agent for Applicants
Reg. No. 42,573

DAG/rk
Atty. Docket No. **040677**
Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930



23850

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449; Supplementary European Search Report; References (13)



INFORMATION DISCLOSURE CITATION PTO-1449	Utility Docket No. 040677	Serial No. 10/517,605
	Applicant(s): YAMADA, Yoshiji, et al.	
	Filing Date: December 21, 2004	Group Art Unit: 3762

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
/KH/	AA	2005-0089914	Yamasaki	04/28/2005		
	AB					

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Translation (Yes or No)
/KH/	AC	01/79234	10/25/2001	PCT
/KH/	AD	91/13075	09/05/1991	PCT
/KH/	AE	01/18250	03/15/2001	PCT
/KH/	AF	03/087360	10/23/2003	PCT
	AG			Abstract only.

OTHER DOCUMENTS


/KH/	AH	PASTINEN, T., et al. "Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population;" <i>Human Molecular Genetics</i> ; Vol. 7, No. 9; pp.1453-1462 (1998).
/KH/	AI	LI, A., et al. "Relationship of the C242T <i>p22phox</i> Gene Polymorphism to Angiographic Coronary Artery Disease and Endothelial Function;" <i>American Journal of Medical Genetics</i> ; Vol. 86, pp.57-61 (1999).
/KH/	AJ	RAURAMAA, R., et al. "Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery Atherosclerosis;" <i>Arterioscler Thromb Vasc Biol.</i> ; Vol. 20; pp.2657-2662 (2000).
/KH/	AK	HUMPHRIES, S., et al. "The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study;" <i>Atherosclerosis</i> ; Vol. 139, pp.49-56 (1998).

Examiner

/Kenneth Horlick/

Date Considered

05/28/2008



INFORMATION DISCLOSURE CITATION PTO-1449	Atty. Docket No. 040677	Serial No. 10/517,605
Applicant(s): YAMADA, Yoshiji, et al.		
	Filing Date: December 21, 2004	Group Art Unit: 3762

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	BA					
_____	BB					

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	BC		
_____	BD		

OTHER DOCUMENTS

/KH/	BE	YE, S., et al. "Progression of Coronary Atherosclerosis Is Associated with a Common Generic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression;" <i>The Journal of Biological Chemistry</i> ; Vol. 271, No. 22. pp.13055-13060 (1996).
/KH/	BF	BOEKHOLDT, S., et al. "Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction;" <i>Circulation</i> ; Vol. 104, pp.3063-3068 (2001).
/KH/	BG	YAMADA, Y., et al. "PREDICTION OF THE RISK OF MYOCARDIAL INFARCTION FROM POLYMORPHISMS IN CANDIDATE GENES;" <i>The New England Journal of Medicine</i> ; Vol.347, No. 24, pp. 1916-1923 (2002).
/KH/	BH	GRUTTERS, J., et al. "Increased Frequency of the Uncommon Tumor Necrosis Factor-857T allele in British and Dutch Patients with Sarcoidosis;" <i>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE</i> ; Vol. 165, pp.1119-1124 (2002).

Examiner

/Kenneth Horlick/

Date Considered

05/28/2008